These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 21486215)

  • 1. Drug resistance: challenges to effective therapy.
    Shekhar MP
    Curr Cancer Drug Targets; 2011 Jun; 11(5):613-23. PubMed ID: 21486215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecules modulating tumor-stromal cell interactions: new candidates for anti-tumor drugs.
    Kawada M
    J Antibiot (Tokyo); 2016 Jun; 69(6):411-4. PubMed ID: 27005556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
    Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
    Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor microenvironment and therapeutic resistance process].
    Borriello L; DeClerck YA
    Med Sci (Paris); 2014 Apr; 30(4):445-51. PubMed ID: 24801042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrins and extracellular matrix: a novel mechanism of multidrug resistance.
    Elliott T; Sethi T
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):449-59. PubMed ID: 12647988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro tumor microenvironment models containing physical and biological barriers for modelling multidrug resistance mechanisms and multidrug delivery strategies.
    Rahmanian M; Seyfoori A; Ghasemi M; Shamsi M; Kolahchi AR; Modarres HP; Sanati-Nezhad A; Majidzadeh-A K
    J Control Release; 2021 Jun; 334():164-177. PubMed ID: 33895200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer chemoresistance; biochemical and molecular aspects: a brief overview.
    Kachalaki S; Ebrahimi M; Mohamed Khosroshahi L; Mohammadinejad S; Baradaran B
    Eur J Pharm Sci; 2016 Jun; 89():20-30. PubMed ID: 27094906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor microenvironment and therapeutic response.
    Wu T; Dai Y
    Cancer Lett; 2017 Feb; 387():61-68. PubMed ID: 26845449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance.
    Maacha S; Bhat AA; Jimenez L; Raza A; Haris M; Uddin S; Grivel JC
    Mol Cancer; 2019 Mar; 18(1):55. PubMed ID: 30925923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tumor microenvironment is a dominant force in multidrug resistance.
    Correia AL; Bissell MJ
    Drug Resist Updat; 2012; 15(1-2):39-49. PubMed ID: 22335920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanodrug delivery systems for targeting the endogenous tumor microenvironment and simultaneously overcoming multidrug resistance properties.
    Li R; Xie Y
    J Control Release; 2017 Apr; 251():49-67. PubMed ID: 28232226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials.
    Fang H; Declerck YA
    Cancer Res; 2013 Aug; 73(16):4965-77. PubMed ID: 23913938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy.
    Ullah MF
    Asian Pac J Cancer Prev; 2008; 9(1):1-6. PubMed ID: 18439063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor microenvironment-mediated chemoresistance in breast cancer.
    Velaei K; Samadi N; Barazvan B; Soleimani Rad J
    Breast; 2016 Dec; 30():92-100. PubMed ID: 27668856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor microenvironment and cancer therapy resistance.
    Sun Y
    Cancer Lett; 2016 Sep; 380(1):205-15. PubMed ID: 26272180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.